In addition to those conducted for cancer, pre-clinical and clinical studies were performed to evaluate the efficacy of saracatinib in Alzheimer’s disease (AD) treatment, considering the association between Fyn and the cascade Aβ-PRPc [5,6]. Here, FYN is linked to Alzheimer disease.